Middle Molecular Uremic Toxin and Blood Purification Therapy.
MCO-membrane
blood purification
hemodiafiltration
middle molecules
α1-microglobulin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Jan 2024
23 Jan 2024
Historique:
received:
21
12
2023
revised:
18
01
2024
accepted:
20
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
10
2
2024
Statut:
epublish
Résumé
The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5-58 kDa, and new classifications of "small-middle 0.5-15 kDa," "medium-middle 15-25 kDa," and "large-middle 25-58 kDa" were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.
Identifiants
pubmed: 38337341
pii: jcm13030647
doi: 10.3390/jcm13030647
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng